fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease.

BACKGROUND AND PURPOSE Functional MR imaging (fMRI) has been used to probe basal ganglia function in people with presymptomatic Huntington's disease (pre-HD). A previous fMRI study in healthy individuals demonstrated activation of the basal ganglia during a time-discrimination task. The current study was designed to examine the relative sensitivity of fMRI compared with that of behavioral testing and morphometric measurements in detecting early neurodegenerative changes related to Huntington's disease (HD). METHODS Pre-HD participants were assigned to two groups based on estimated years to diagnosis of manifest disease: close <12 years and far >or=12 years. Age at disease onset was estimated using a regression equation based on the number of trinucleotide CAG repeats. The time-discrimination task required participants to determine whether a specified interval was shorter or longer than a standard interval of 1200 milliseconds. RESULTS Participants in the close group performed more poorly on the time-task discrimination than did control subjects; however, no differences were observed between far participants and control subjects. Similarly, close participants had reduced bilateral caudate volume relative to that of control subjects, whereas far participants did not. On functional imaging, close participants had significantly less activation in subcortical regions (caudate, thalamus) than control subjects; far participants had an intermediate degree of activation. In contrast, far participants had hyperactivation in medial hemispheric structures (anterior cingulate, pre-supplementary motor area) relative to close and control subjects. CONCLUSION Hyperactivation of medial prefrontal regions compensated for reduced subcortical participation during time discrimination in pre-HD. This pattern of brain activation may represent an early neurobiologic marker of neuronal dysfunction.

[1]  R. C. Oldfield The assessment and analysis of handedness: the Edinburgh inventory. , 1971, Neuropsychologia.

[2]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[3]  J. B. Martin,et al.  Clinical and neuropathologic assessment of severity in Huntington's disease , 1988, Neurology.

[4]  J. Talairach,et al.  Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging , 1988 .

[5]  J. Penney,et al.  Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. , 1990, The New England journal of medicine.

[6]  Christopher A. Ross,et al.  Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease , 1991, Neuroscience Letters.

[7]  R. S. Williams,et al.  Morphometric analysis of the prefrontal cortex in Huntington's disease , 1991, Neurology.

[8]  S. Folstein,et al.  Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease , 1992, Annals of neurology.

[9]  J. Penney,et al.  Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's disease , 1992, Annals of neurology.

[10]  J A Obeso,et al.  Temporal discrimination is abnormal in Parkinson's disease. , 1992, Brain : a journal of neurology.

[11]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[12]  J. Brandt,et al.  Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at‐risk persons , 1994, Neurology.

[13]  S. Folstein,et al.  Selective Loss of [3H]Kainic Acid and [3H]AMPA Binding in Layer VI of Frontal Cortex in Huntington's Disease , 1994, Experimental Neurology.

[14]  E. Siemers,et al.  Cognitive scores in carriers of huntington's disease gene compared to noncarriers , 1995, Annals of neurology.

[15]  G. Pearlson,et al.  Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. , 1996, Archives of neurology.

[16]  R W Cox,et al.  AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. , 1996, Computers and biomedical research, an international journal.

[17]  F. W. Cody,et al.  The accuracy and precision of timing of self-paced, repetitive movements in subjects with Parkinson's disease. , 1996, Brain : a journal of neurology.

[18]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[19]  J. Brandt,et al.  Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[20]  D. Woodruff-Pak,et al.  Huntington's disease and eyeblink classical conditioning: Normal learning but abnormal timing , 1996, Journal of the International Neuropsychological Society.

[21]  D. Brooks,et al.  Cortical control of movement in Huntington's disease. A PET activation study. , 1997, Brain : a journal of neurology.

[22]  S. Shirato,et al.  Mutations in the TIGR gene in familial primary open-angle glaucoma in Japan. , 1997, American journal of human genetics.

[23]  A Weindl,et al.  Central motor processing in Huntington's disease. A PET study. , 1997, Brain : a journal of neurology.

[24]  M. Hayden,et al.  The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. , 1997, American journal of human genetics.

[25]  A E Rosser,et al.  Evidence for specific cognitive deficits in preclinical Huntington's disease. , 1998, Brain : a journal of neurology.

[26]  D. Harrington,et al.  Temporal processing in the basal ganglia. , 1998, Neuropsychology.

[27]  J. Brandt,et al.  When does Huntington's disease begin? , 1998, Journal of the International Neuropsychological Society.

[28]  J. Brandt,et al.  Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. , 1999, Brain : a journal of neurology.

[29]  T. Rammsayer,et al.  Neuropharmacological Evidence for Different Timing Mechanisms in Humans , 1999, The Quarterly journal of experimental psychology. B, Comparative and physiological psychology.

[30]  S. Hersch,et al.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.

[31]  J L Lancaster,et al.  Automated Talairach Atlas labels for functional brain mapping , 2000, Human brain mapping.

[32]  G. Pearlson,et al.  Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[33]  A. Tobin,et al.  Huntington's disease: the challenge for cell biologists. , 2000, Trends in cell biology.

[34]  C. Cepeda,et al.  NMDA receptor function in mouse models of Huntington disease , 2001, Journal of neuroscience research.

[35]  M. Schwaiger,et al.  Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. , 2001, Brain : a journal of neurology.

[36]  Jane S. Paulsen,et al.  Clinical markers of early disease in persons near onset of Huntington’s disease , 2001, Neurology.

[37]  J. Cherry,et al.  Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse. , 2001, Biochimica et biophysica acta.

[38]  Armin Schnider,et al.  Time estimation in Parkinson's disease: normal long duration estimation despite impaired short duration discrimination , 2001, Journal of Neurology.

[39]  Stephen M. Rao,et al.  The evolution of brain activation during temporal processing , 2001, Nature Neuroscience.

[40]  S. Hersch,et al.  Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice , 2003, Journal of neurochemistry.

[41]  Jane S. Paulsen,et al.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length , 2004, Clinical genetics.

[42]  R. Church,et al.  The differential effects of haloperidol and methamphetamine on time estimation in the rat , 2004, Psychopharmacology.

[43]  S. Folstein,et al.  Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study , 1992, Neuroradiology.